Thymosin Beta-4 vs Vasoactive Intestinal Peptide (VIP)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Thymosin Beta-4
Thymosin Beta-4 (TB4) is the full-length 43-amino acid peptide produced naturally in high concentrations in platelets, wound fluid, and regenerating tissue. It is the parent molecule from which the popular TB-500 research peptide (the 17-23 fragment Ac-LKKTETQ) is derived. TB4 promotes actin polymerization, accelerates wound healing, reduces inflammation, and supports cardiac and neurological repair in preclinical models.
Full profileVasoactive Intestinal Peptide (VIP)
28-amino acid neuropeptide found throughout the CNS, gut, and immune system. Functions as a potent anti-inflammatory, vasodilator, and neurotrophic factor. Research applications include CIRS (Chronic Inflammatory Response Syndrome), pulmonary arterial hypertension, autoimmune conditions, and gut motility disorders. Intranasal administration is most studied for CIRS and neuroinflammatory conditions.
Full profile| Thymosin Beta-4 | Vasoactive Intestinal Peptide (VIP) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | TB4, Tβ4, Tβ4 full-length | VIP, vasoactive intestinal polypeptide, PHM-27 |
| Evidence | Investigational (in trials) | Investigational (in trials) |
| Dosing range | 500mcg–2000mcg mcg, 2–3x weekly | 25mcg–100mcg mcg, Daily intranasal or 1–2x weekly subcutaneous |
| Administration | Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only) | Intranasal spray, Subcutaneous injection, Inhalation (nebulized) |
| Key side effects | Injection site discomfort (mild), Transient fatigue post-injection, Headache (uncommon), Theoretically may accelerate growth of pre-existing malignant tumors (promotes angiogenesis and cell migration — use with caution) | Facial flushing, Transient hypotension, Nasal irritation (intranasal route), Tachycardia |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Thymosin Beta-4 — Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only); Vasoactive Intestinal Peptide (VIP) — Intranasal spray, Subcutaneous injection, Inhalation (nebulized).
- Frequency: Thymosin Beta-4 is typically 2–3x weekly; Vasoactive Intestinal Peptide (VIP) is Daily intranasal or 1–2x weekly subcutaneous.
- Research depth: this profile cites 3 sources for Thymosin Beta-4 vs 2 for Vasoactive Intestinal Peptide (VIP).
How each works
Thymosin Beta-4
TB4's primary mechanism involves sequestering G-actin monomers (via its LKKTET actin-binding domain) to regulate actin cytoskeleton dynamics — critical for cell migration, wound closure, and tissue remodeling. Clinical trials have evaluated TB4 for corneal wound healing (Phase 2), pressure ulcers, and cardiac repair after MI. The FACT trial investigated TB4 in patients with ischemic heart failure, showing trends toward improved cardiac function. Anti-inflammatory effects are mediated partly through NF-κB pathway downregulation.
Vasoactive Intestinal Peptide (VIP)
VIP activates VPAC1 and VPAC2 receptors coupled to cAMP, suppressing pro-inflammatory cytokines while promoting Th2 regulatory immune responses and Treg differentiation. In the CIRS/biotoxin illness framework pioneered by Shoemaker, VIP intranasal formulation demonstrates normalization of inflammatory markers and improvement in TGF-β, MSH, and VIP deficiency seen in CIRS patients. Pulmonary vasodilation effects have been studied for PAH.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.